Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab Maintenance in High-Risk Cytogenetic Multiple Myeloma
NCT03000634Phase 2Withdrawn
- Sponsor
- University of Arkansas
- Start
- Apr 2017
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by University of Arkansas. Primary endpoint: Percentage of patients without disease progression at 36 months. Planned start Apr 2017; status: withdrawn.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03000634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000634.